Market Closed -
London S.E.
16:35:26 03/05/2024 BST
|
5-day change
|
1st Jan Change
|
9.4
GBX
|
-3.59%
|
|
-4.08%
|
+14.08%
|
Fiscal Period: January |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
25.85
|
14.11
|
10.09
|
78.37
|
172.4
|
93.73
|
Enterprise Value (EV)
1 |
16.25
|
8.202
|
6.32
|
65.37
|
146.4
|
62.33
|
P/E ratio
|
-4.82
x
|
-3.53
x
|
-4.3
x
|
-18.9
x
|
-20.3
x
|
-10.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
320,595,864
x
|
22,132,031
x
|
247,221,047
x
|
361,386,390
x
|
197,321,373
x
|
EV / Revenue
|
-
|
186,414,045
x
|
13,860,101
x
|
206,198,965
x
|
306,956,621
x
|
131,228,741
x
|
EV / EBITDA
|
-2.47
x
|
-1.62
x
|
-2.23
x
|
-16.1
x
|
-15.4
x
|
-6.13
x
|
EV / FCF
|
-5.08
x
|
-2.81
x
|
-4.27
x
|
-28.5
x
|
-25
x
|
-10.6
x
|
FCF Yield
|
-19.7%
|
-35.6%
|
-23.4%
|
-3.5%
|
-4%
|
-9.47%
|
Price to Book
|
2.41
x
|
2.07
x
|
2.24
x
|
5.64
x
|
6.16
x
|
2.84
x
|
Nbr of stocks (in thousands)
|
268,531
|
268,690
|
269,125
|
420,774
|
514,571
|
582,159
|
Reference price
2 |
0.0962
|
0.0525
|
0.0375
|
0.1862
|
0.3350
|
0.1610
|
Announcement Date
|
04/04/18
|
06/03/19
|
31/03/20
|
21/05/21
|
04/05/22
|
04/05/23
|
Fiscal Period: January |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
0.044
|
0.456
|
0.317
|
0.477
|
0.475
|
EBITDA
1 |
-6.586
|
-5.06
|
-2.84
|
-4.049
|
-9.525
|
-10.17
|
EBIT
1 |
-6.648
|
-5.114
|
-2.888
|
-4.085
|
-9.57
|
-10.24
|
Operating Margin
|
-
|
-11,622.73%
|
-633.33%
|
-1,288.64%
|
-2,006.29%
|
-2,155.58%
|
Earnings before Tax (EBT)
1 |
-6.719
|
-5.085
|
-2.873
|
-4.468
|
-9.519
|
-9.772
|
Net income
1 |
-5.359
|
-3.999
|
-2.347
|
-3.684
|
-8.07
|
-8.274
|
Net margin
|
-
|
-9,088.64%
|
-514.69%
|
-1,162.15%
|
-1,691.82%
|
-1,741.89%
|
EPS
2 |
-0.0200
|
-0.0149
|
-0.008729
|
-0.009870
|
-0.0165
|
-0.0154
|
Free Cash Flow
1 |
-3.196
|
-2.92
|
-1.481
|
-2.29
|
-5.85
|
-5.904
|
FCF margin
|
-
|
-6,636.93%
|
-324.78%
|
-722.44%
|
-1,226.52%
|
-1,242.89%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
04/04/18
|
06/03/19
|
31/03/20
|
21/05/21
|
04/05/22
|
04/05/23
|
Fiscal Period: January |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
9.6
|
5.9
|
3.77
|
13
|
26
|
31.4
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-3.2
|
-2.92
|
-1.48
|
-2.29
|
-5.85
|
-5.9
|
ROE (net income / shareholders' equity)
|
-40.1%
|
-45.6%
|
-41.5%
|
-40.1%
|
-38.6%
|
-27.2%
|
ROA (Net income/ Total Assets)
|
-28%
|
-33.2%
|
-29.4%
|
-26.7%
|
-27.1%
|
-19.9%
|
Assets
1 |
19.15
|
12.06
|
7.993
|
13.78
|
29.73
|
41.47
|
Book Value Per Share
2 |
0.0400
|
0.0300
|
0.0200
|
0.0300
|
0.0500
|
0.0600
|
Cash Flow per Share
2 |
0.0300
|
0.0200
|
0.0100
|
0.0300
|
0.0200
|
0.0500
|
Capex
1 |
0.07
|
0.01
|
0.01
|
0.05
|
0.11
|
0.07
|
Capex / Sales
|
-
|
18.18%
|
1.1%
|
16.72%
|
22.22%
|
14.32%
|
Announcement Date
|
04/04/18
|
06/03/19
|
31/03/20
|
21/05/21
|
04/05/22
|
04/05/23
|
|
1st Jan change
|
Capi.
|
---|
| +14.08% | 68.94M | | +25.69% | 47.86B | | +46.90% | 41.42B | | -3.46% | 40.66B | | -6.20% | 28.92B | | +9.17% | 25.55B | | -20.42% | 19.27B | | +0.17% | 12.15B | | +28.07% | 12.14B | | -1.24% | 11.99B |
Other Biotechnology & Medical Research
|